Can a cancer pill keep working outside the lab? a Real-World test begins

NCT ID NCT04553926

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study monitors the safety and effectiveness of the drug olaparib (Lynparza) in people with ovarian, breast, prostate, or pancreatic cancer who are prescribed it as part of routine care in South Korea. Researchers will track side effects and how long the cancer stays under control without requiring extra study visits. The goal is to see how well the drug performs in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a PARP inhibitor drug called olaparib (Lynparza)
What this could lead to: If successful, this study could confirm that olaparib works safely in everyday clinical practice for several cancers.
What could go wrong: This is an observational post-marketing study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by how doctors choose treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Research Site

Ansan, South Korea
Research Site

Bucheon-si, South Korea
Research Site

Busan, South Korea
Research Site

Changwon, South Korea
Research Site

Daegu, South Korea
Research Site

Daejeon, South Korea
Research Site

Goyang, South Korea
Research Site

Gunpo, South Korea
Research Site

Hwaseong, South Korea
Research Site

Ilsan, South Korea
Research Site

Incheon, South Korea
Research Site

Jeonju, South Korea
Research Site

Seongnam, South Korea
Research Site

Seoul, South Korea
Research Site

Suwon, South Korea
Research Site

Uijeongbu-si, South Korea
Research Site

Yangsan, South Korea
Research Site

Yongin, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.